Matching-adjusted comparison of oral corticosteroid reduction in asthma: Systematic review of biologics.

ABSTRACT:

Background

Oral corticosteroid (OCS) treatment for severe asthma is associated with substantial disease burden. Thus, OCS dosage reduction is desirable. Relative efficacy of biologics in reducing OCS treatment for severe, uncontrolled asthma is not fully characterized.

Objective

We performed a matching-adjusted indirect comparison (MAIC) to assess the relative effects on OCS treatment reduction of three biologic asthma treatments.

Methods

In MAIC of benralizumab vs. mepolizumab and vs. dupilumab, patient-level data from the Phase III benralizumab OCS-sparing trial, ZONDA, were weighted to match treatment effect-modifying patient characteristics in comparator trials.

Results

After matching adjustment, mean difference between benralizumab and mepolizumab for OCS

SUBMITTER: Bourdin A 

PROVIDER: S-EPMC7204869 | biostudies-literature | 2020 Apr

REPOSITORIES: biostudies-literature